Apr 01, 2020
Salimetrics' Growing List of Cytokines Which Can Be Reliably Tested in Saliva Now Includes IL-17A, IL-5, and IL-7 for Fast, Easy Salivary Biomarker Analysis
Nov 15, 2019
Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Oct 17, 2019
Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
Oct 03, 2019
Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments
Sep 11, 2019
AllianceRx Walgreens Prime study demonstrates increased adherence and improvement in symptoms for psoriasis patients switching to interleukin-17 inhibitors
Jul 26, 2019
Th17 Inflammatory Pathway Therapeutics Markets, 2022
Jan 28, 2019
Novartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
Oct 23, 2018
Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
Oct 22, 2018
Novartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitis
Aug 22, 2018
Nuevolution Discloses the Identity of its "Cytokine X" Program being Interleukin IL-17A and Initiates Promotion of its Small Molecule IL-17A Inhibitor Program Targeting Inflammatory Diseases
Feb 19, 2018
AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Feb 08, 2018
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
Jan 16, 2018
Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
Oct 30, 2017
Psoriasis Drugs Market Size Worth $21.44 Billion by 2022 | CAGR: 9.3%: Grand View Research, Inc.
Oct 12, 2017
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ(TM) (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Sep 13, 2017
Novartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data